Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5898465 | 0.95 | NOS3 (0.40) | ACHENOS3NOS2KDM5BRECQL | |
| SCHEMBL4270536 | 0.88 | ACHE (0.52) | ACHERECQLCCR1HSD17B10KDM4E | |
| SCHEMBL2747792 | 0.83 | NOS3 (0.39) | ACHENOS3NOS2KDM5BRECQL | |
| SCHEMBL31209938 | 0.82 | PTGS2 (0.46) | NOS2CYP1A2POLBHSD17B10KDM4E | |
| SCHEMBL20072591 | 0.82 | NOS2 (0.57) | NOS3NOS2KDM5BCCR1 | |
| SCHEMBL16346209 | 0.81 | RECQL (0.47) | ACHENOS3NOS2KDM5BRECQL | |
| SCHEMBL16345715 | 0.81 | NOS2 (0.57) | NOS3NOS2 | |
| SCHEMBL26241406 | 0.80 | NOS3 (0.45) | NOS3NOS2KDM5BCCR1CYP1A2 | |
| SCHEMBL8235724 | 0.79 | KCNH2 (0.50) | ACHENOS2HSD17B10KDM4EALDH1A1 | |
| SCHEMBL6465582 | 0.78 | NOS3 (0.44) | NOS3NOS2KDM5BCYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-01-18 | — | — | US | disclosed |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225469-B2 | Inhibitors of phosphoglycerate dehydrogenase (PHGDH) and uses thereof | PHGDH, PGD, PGK1 | ACHE 3416/4885NOS3 2640/4885NOS2 2906/4885 |
| US-20180105508-A1 | INHIBITORS OF PHOSPHOGLYCERATE DEHYDROGENASE (PHGDH) AND USES THEREOF | PHGDH, PGD, PGK1 | ACHE 2915/4885NOS3 2532/4885NOS2 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.